CSIR-IMTech (CSIR, Institute of Microbial Technology, Government of India) has entered into a new collaboration with global pharmaceutical company, Johnson and Johnson for development of new drugs for treatment of tuberculosis (TB). The Johnson and Johnson have recently developed a “Bedaquiline” for treatment of drug-resistant TB and has been approved by several countries of world including US, Europe and India. To further engage in next-generation of TB drug discovery, a Memorandum of Understanding (MoU) has been signed between IMTECH and Johnson & Johnson for collaborative research on TB.(https://www.imtech.res.in/about/institutional-highlights/csir-imtech-signs-mou-with-johnson-and-johnson-for-collaborative-research-on-tb. )
New Delhi, August 16, 2017: Johnson & Johnson Private Limited today announced a new partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to unlock the potential of Indian science and help accelerate the discovery of innovative new treatments for tuberculosis (TB).
Under the Memorandum of Understanding, scientists from Johnson & Johnson’s global public health team will work closely with scientists from CSIR-IMTECH, based in Chandigarh, India, on a research and development program to explore potentially more effective, safer, all-oral treatment regimens to tackle multidrug-resistant TB (MDR-TB), as well as new molecular entities to treat all TB patients. ( https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-partnership-with-csir-imtech-to-develop-innovative-new-tuberculosis-treatments )
Director of CSIR-IMTECH is Dr. Anil Koul
URL:
Internal Notes:
Announced by RESIST-TB in 2017. Barbara wrote to Anil Koul but did not receive a reply.
CSIR-IMTECH webpage (Sept 18, 2018)
New email = director@imtech.res.in/ anilkoul@imtech.res.in
Institute of Microbial Technology (IMTECH)
Council of Scientific and Industrial Research (Governement of India)
Sector -39A, Chandigarh
Pin- 160036 (India)
(tel) 1726665100
Dr. Anil Koul, prior to taking the charge of Director, CSIR-IMTech, was Senior Director & Head, Respiratory Infections Discovery group at healthcare multinational Johnson & Johnson. He has more than 16 years of experience in pharmaceutical drug discovery research and clinical development. He obtained his Ph.D. from Max-Planck Institute for Biochemistry in Munich, Germany and Delhi University, Delhi. As a part of continued education, in 2011, he attended a short residential program at Harvard Business School, USA on innovation, strategy and leadership.